Skip to main content
13 August 2026
07 January 2026

Amgen Strengthens Oncology Pipeline with Dark Blue Therapeutics Acquisition

Amgen announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom advancing first-in-class, small molecule-targeted protein degraders for oncology, in a transaction valued at up to $840 million.   The acquisition adds to Amgen's portfolio an investigati…

06 January 2026

Sanofi Partners with Earendil Labs to Advance AI-Discovered Bispecific Therapies

Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, announced a strategic collaboration with Sanofi to apply Earendil's discovery platform to multiple autoimmune and inflammatory disease programs. Sanofi will lead the development and worldwide commercializati…

05 January 2026

Insilico Medicine, Servier collaborate on AI-driven oncology drug development

Insilico Medicine, a world-leading artificial intelligence (AI)-driven drug discovery company, announced a multi-year research and development (R&D) collaboration with Servier, an independent international pharmaceutical company governed by a foundation. This strategic alliance is focused on identifying and develo…

02 January 2026

Brenntag strengthens ANZ industrial chemicals footprint via Henan Yongchang agreement

Brenntag, the global leader in chemicals and ingredients distribution, has signed an exclusive distribution agreement with Henan Yongchang Nitro Fertilizer Co., Ltd. for nitric acid, covering the markets of Australia and New Zealand.   Henan Yongchang is a long-established chemical producer based in Huixian City in …

31 December 2025

Transcenta, EirGenix Collaborate to Scale Next-Generation Bioprocessing

Transcenta Holding Limited, a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announced it has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc., a glob…

30 December 2025

ABL Bio and Eli Lilly Expand Grabody Collaboration with USD 55M Commitment

ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that ABL Bio will receive a USD 40 million upfront payment for the license, research and collaboration agreement for its Grabody platform, and a USD 15 million equity investment from Eli Lilly and Company ("Lilly"). ABL Bio and Li…

29 December 2025

Pfizer India and Cipla strengthen collaboration for Indian market

Pfizer India and Cipla Limited announced a partnership where Cipla will exclusively market and distribute four brands of Pfizer in India. Under the agreement, Cipla now has the sole right to market, distribute and sell the cough syrup Corex Dx and Corex LS, the non-steroidal anti-inflammatory drug (NSAID) Dolonex, th…

29 December 2025

Harbour BioMed expands therapeutic platform through strategic Lannacheng deal

Harbour BioMed, a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it has entered into a long-term strategic collaboration with Yantai Lannacheng Biotechnology Co., Ltd. ("Lannacheng"). The two parties will lever…

Page 19 of 36